AD/PD 2022 | Using plasma biomarkers in the diagnosis of Alzheimer’s disease

Charlotte Teunissen • 17 Mar 2022

AD/PD 2022

Charlotte Teunissen, PhD, VU University Medical Center Amsterdam, Amsterdam, The Netherlands, comments on the potential contribution of plasma biomarkers for a reliable and accurate diagnosis of Alzheimer’s disease. Rapid progress has been made in recent years, with data accumulating to support the clinical value of several plasma biomarkers, including phosphorylated tau (p-tau) isoforms, amyloid beta (Aβ) isoforms, GFAP, and neurofilament light (NfL). Dr Teunissen discusses where these markers are likely to fit in the diagnostic work up of Alzheimer’s disease, highlighting that it is too early to rely solely on plasma biomarkers for diagnosis. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.

Disclosures

Grants: Research of CET is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) and JPND (bPRIDE), National MS Society (Progressive MS alliance) and Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association. CT is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. CET has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Biogen, Bioorchstra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Novo Nordisk, PeopleBio, Roche, Toyama, Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is editor of a Neuromethods book Springer.
Speaker contract: Roche